Filtern
Volltext vorhanden
- ja (27)
Gehört zur Bibliographie
- ja (27)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (27)
Schlagworte
- glioblastoma (8)
- glioblastoma multiforme (5)
- astrocytoma (4)
- recurrence (4)
- Glioblastoma (3)
- therapy (3)
- CNS disorders (2)
- MPS1 (2)
- blood–brain barrier (2)
- glioma (2)
- low-grade glioma (2)
- mRNA (2)
- organoids (2)
- protein (2)
- relapse (2)
- temozolomide (2)
- vestibular schwannoma (2)
- 3D ex vivo models (1)
- 3D in vitro model (1)
- ADAM9 (1)
- Astrocytic tumor (1)
- Bevacizumab (1)
- CD133 (1)
- CNS diseases (1)
- CXCR4 (1)
- Combination (1)
- EBRT (1)
- Expression (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- Glioma stem cells (1)
- HERV-K (1)
- Human endogenous retrovirus (1)
- IDH (1)
- IDH1/2 (1)
- ISBI (1)
- Immunostimulatory adjuvant (1)
- Immunotherapy (1)
- Irradiation (1)
- MGMT (1)
- MGMT promoter methylation (1)
- Medizin (1)
- Meningioma (1)
- Merlin (1)
- Nestin (1)
- Oncolysis (1)
- Osteopontin (1)
- PCR analysis (1)
- PET/CT (1)
- PRRT (1)
- Pentixafor (1)
- Peptide receptor radionuclide therapy (1)
- RS-13 (1)
- Radiotherapy (1)
- SOAT1 (1)
- Spinal dissemination (1)
- Staphylococcus (1)
- TTFields (1)
- TTK (1)
- Temozolomide (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-Treating Fields (TTFields) (1)
- \(^{68}\)Ga-Pentixafor (1)
- aging (1)
- amyloidoma (1)
- anticancer activity (1)
- behavior (1)
- blood-brain barrier (1)
- brain (1)
- brain tumor (1)
- cancer stem cells (1)
- chemokine receptor-4 (1)
- chemotherapy (1)
- depression (1)
- diffuse astrocytoma (1)
- distress (1)
- expression (1)
- glioblastoma multiforme (GBM) (1)
- growth pattern (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cells (1)
- imaging (1)
- immunofuorescence double staining (1)
- immunostaining (1)
- in vitro model (1)
- integrin (1)
- internalized stigmatization (1)
- knock down (1)
- lipid droplets (1)
- liponeurocytoma (1)
- liquid biopsy (1)
- lower grade glioma (1)
- mRNA expression (1)
- macrophages (1)
- magnetic resonance imaging (1)
- medulloblastoma (1)
- metastasis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- microglial cells (1)
- mitotane (1)
- molecular imaging (1)
- molecular signature (1)
- multifocal growth (1)
- nausea and emesis (1)
- neurocytoma (1)
- neurodegenerative disease (1)
- neurooncology (1)
- neurovascular unit (1)
- occupation (1)
- oligodendroglioma (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- pain (1)
- palladium (1)
- pathogenesis (1)
- platinum (1)
- positron emission tomography (1)
- positron emission tomography/computed tomography (1)
- primary cell culture (1)
- prognostic marker (1)
- protein and mRNA expression (1)
- quality of life (1)
- resilience (1)
- resistance (1)
- senescence (1)
- slice culture (1)
- somatostatin (1)
- suppressor (1)
- targeted therapy (1)
- therapy response (1)
- thiosemicarbazone (1)
- tumor slice cultures (1)
- tumormicroenvironment (1)
Institut
- Neurochirurgische Klinik und Poliklinik (24)
- Pathologisches Institut (16)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
- Neurologische Klinik und Poliklinik (3)
- Klinik und Poliklinik für Strahlentherapie (2)
- Frauenklinik und Poliklinik (1)
- Institut für Anorganische Chemie (1)
- Institut für Rechtsmedizin (1)
- Kinderklinik und Poliklinik (1)
The metastatic suppressor BRMS1 interacts with critical steps of the metastatic cascade in many cancer entities. As gliomas rarely metastasize, BRMS1 has mainly been neglected in glioma research. However, its interaction partners, such as NFκB, VEGF, or MMPs, are old acquaintances in neurooncology. The steps regulated by BRMS1, such as invasion, migration, and apoptosis, are commonly dysregulated in gliomas. Therefore, BRMS1 shows potential as a regulator of glioma behavior. By bioinformatic analysis, in addition to our cohort of 118 specimens, we determined BRMS1 mRNA and protein expression as well as its correlation with the clinical course in astrocytomas IDH mutant, CNS WHO grade 2/3, and glioblastoma IDH wild-type, CNS WHO grade 4. Interestingly, we found BRMS1 protein expression to be significantly decreased in the aforementioned gliomas, while BRMS1 mRNA appeared to be overexpressed throughout. This dysregulation was independent of patients’ characteristics or survival. The protein and mRNA expression differences cannot be finally explained at this stage. However, they suggest a post-transcriptional dysregulation that has been previously described in other cancer entities. Our analyses present the first data on BRMS1 expression in gliomas that can provide a starting point for further investigations.